II 

Calendar No. 118 

110TH CONGRESS 

1ST SESSION S. 3 

To amend part D of title XVIII of the Social Security Act to provide 

for fair prescription drug prices for Medicare beneficiaries. 

IN THE SENATE OF THE UNITED STATES 

JANUARY 4, 2007 

Mr. REID (for himself, Mr. BAUCUS, Mr. LEAHY, Ms. MIKULSKI, Mr. SCHUMER, Mrs. CLINTON, Ms. CANTWELL, Mr. KOHL, Ms. STABENOW, Mr. 

WEBB, Mrs. BOXER, Mr. BROWN, Ms. KLOBUCHAR, Mr. CASEY, and Mr. 

LEVIN) introduced the following bill; which was read twice and referred 

to the Committee on Finance 

APRIL 13, 2007 

Reported under authority of the order of the Senate of April 12, 2007, by 

Mr. BAUCUS, with an amendment 

[Strike out all after the enacting clause and insert the part printed in italic] 

A BILL 

To amend part D of title XVIII of the Social Security 

Act to provide for fair prescription drug prices for Medicare beneficiaries. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


jlentini on PROD1PC65 with BILLS
2 

•S 3 RS

1 SECTION 1. SHORT TITLE; SENSE OF THE CONGRESS. 

2 (a) SHORT TITLE.—This Act may be cited as the 

3 ‘‘Medicare Prescription Drug Price Negotiation Act of 

4 2007’’. 

5 (b) SENSE OF THE CONGRESS.—It is the sense of 

6 the Congress that the Congress should enact, and the 

7 President should sign, legislation to amend part D of title 

8 XVIII of the Social Security Act to provide for fair pre9 scription drug prices for Medicare beneficiaries. 

10 SECTION 1. SHORT TITLE. 

11 This Act may be cited as the ‘‘Medicare Fair Prescrip12 tion Drug Price Act of 2007’’. 

13 SEC. 2. REPEAL OF PROHIBITION. 

14 (a) REPEAL OF PROHIBITION.— 

15 (1) IN GENERAL.—Section 1860D–11(i) of the 

16 Social Security Act (42 U.S.C. 1395w–111(i)) is 

17 amended by striking ‘‘the Secretary—’’ and all that 

18 follows through ‘‘may not require’’ and inserting ‘‘the 

19 Secretary may not require’’. 

20 (2) RULE OF CONSTRUCTION.—Nothing in the 

21 amendment made by paragraph (1) shall be construed 

22 as doing any of the following: 

23 (A) Preventing the sponsor of a prescription 

24 drug plan or an MA organization offering an 

25 MA–PD plan under part D of title XVIII of the 


jlentini on PROD1PC65 with BILLS
3 

•S 3 RS

1 Social Security Act from obtaining a discount or 

2 reduction of the price for a covered part D drug. 

3 (B) Affecting the authority of the Secretary 

4 of Health and Human Services to ensure appro5 priate and adequate access to covered part D 

6 drugs under prescription drug plans and under 

7 MA–PD plans under such part, including com8 pliance of such plans with formulary require9 ments under section 1860D–4(b)(3) of the Social 

10 Security Act (42 U.S.C. 1395w–104(b)(3)). 

11 (C) Limiting access by individuals enrolled 

12 in such prescription drug plans and MA–PD 

13 plans to community pharmacies. 

14 (3) CONDUCT OF NEGOTIATIONS.—Section 

15 1860D–11 of the Social Security Act (42 U.S.C. 

16 1395w–111) is amended by adding at the end the fol17 lowing new subsection: 

18 ‘‘(k) EFFORTS TO PROMOTE AND ENSURE ACCESS TO

19 FAIR PRICES.— 

20 ‘‘(1) USE OF AGENCY RESOURCES.—To the ex21 tent that the Secretary promotes and ensures access to 

22 fair prices by engaging in any direct negotiations 

23 with a drug manufacturer with respect to prices for 

24 covered part D drugs, the Secretary— 


jlentini on PROD1PC65 with BILLS
4 

•S 3 RS

1 ‘‘(A) may only do so utilizing the resources 

2 of the Department of Health and Human Serv3 ices; and 

4 ‘‘(B) may not enter into a contract with 

5 any public or private entity or enter into an 

6 Interdepartmental Agreement for the purpose of 

7 conducting such negotiations.’’. 

8 (b) ACCOUNTABILITY.—Section 1860D–11(k) of the So9 cial Security Act, as added by subsection (a)(3), is amended 

10 by adding at the end the following new paragraph: 

11 ‘‘(2) ANNUAL REPORT ON EFFORTS TO PROMOTE

12 AND ENSURE ACCESS TO FAIR PRICES.—The Sec13 retary shall submit to Congress an annual report on 

14 the efforts of the Secretary to promote and ensure ac15 cess to fair prices for prescription drugs under this 

16 part.’’. 

17 (c) EFFECTIVE DATE.—The amendments made by this 

18 section shall take effect on the date of enactment of this Act. 

19 SEC. 3. GREATER TRANSPARENCY OF PART D PRICES AND 

20 INFORMATION. 

21 (a) ACCESS OF CONGRESSIONAL SUPPORT AGENCIES

22 TO DATA ON PRESCRIPTION DRUG PLANS AND MEDICARE

23 ADVANTAGE PLANS.—Section 1860D–42 of the Social Secu24 rity Act (42 U.S.C. 1395w–152) is amended by adding at 

25 the end the following new subsection: 


jlentini on PROD1PC65 with BILLS
5 

•S 3 RS

1 ‘‘(c) PROVIDING PART D DATA TO CONGRESSIONAL

2 SUPPORT AGENCIES.— 

3 ‘‘(1) IN GENERAL.—Notwithstanding any provi4 sion under this part that limits the use of prescrip5 tion drug data collected under this part and subject 

6 to the restriction under paragraph (6), upon the re7 quest of a congressional support agency, the Secretary 

8 shall provide such agency with the following data col9 lected from, or related to, prescription drug plans and 

10 MA–PD plans: 

11 ‘‘(A) AGGREGATE NEGOTIATED PRICE CON12 CESSIONS.—Aggregate negotiated price conces13 sions described in section 1860D–2(d)(2) (as de14 termined necessary and appropriate by the con15 gressional support agency to carry out the legis16 latively mandated duties of the agency). 

17 ‘‘(B) NEGOTIATED PRICE CONCESSIONS.— 

18 The negotiated rebates, discounts, and other price 

19 concessions (as currently reported pursuant to 

20 section 1860D–2(d)(2)). 

21 ‘‘(C) DRUG CLAIMS DATA.—Data or a rep22 resentative sample of data regarding drug claims 

23 submitted under section 1860D–15(c)(1)(C) (as 

24 determined necessary and appropriate by the 


jlentini on PROD1PC65 with BILLS
6 

•S 3 RS

1 congressional support agency to carry out the 

2 legislatively mandated duties of the agency). 

3 ‘‘(D) REINSURANCE PAYMENTS.—The 

4 amount of reinsurance payments paid under sec5 tion 1860D–15(a)(2), provided at the plan level. 

6 ‘‘(E) RISK-CORRIDOR PAYMENTS.—The 

7 amount of any adjustments of payments made 

8 under subparagraph (B) or (C) of section 

9 1860D–15(e)(2), provided at the plan level. 

10 ‘‘(2) PROHIBITION ON DISCLOSURE OF DATA BY

11 CONGRESSIONAL SUPPORT AGENCIES.— 

12 ‘‘(A) Data provided to a congressional sup13 port agency under this subsection shall not— 

14 ‘‘(i) be disclosed by such agency in the 

15 performance of the agency’s duties in cases 

16 where such disclosure by the Secretary 

17 would be prohibited under applicable Fed18 eral law, or where such disclosure would re19 sult in the disclosure of trade secrets; and 

20 ‘‘(ii) be disclosed, reported, or released 

21 by such agency in identifiable form. 

22 ‘‘(B) IDENTIFIABLE FORM.—For purposes of 

23 subparagraph (A)(ii), the term ‘identifiable 

24 form’ means any representation of information 

25 described in subparagraphs (A) through (E) of 


jlentini on PROD1PC65 with BILLS
7 

•S 3 RS

1 paragraph (1) that permits identification of a 

2 specific prescription drug plan, MA–PD plan, 

3 pharmacy benefit manager, drug manufacturer, 

4 drug wholesaler, drug, or individual enrolled in 

5 a prescription drug plan or an MA–PD plan 

6 under this part. 

7 ‘‘(3) SAFEGUARDING DATA.—Each congressional 

8 support agency shall adopt and maintain reasonable 

9 safeguards to protect against the unauthorized disclo10 sure of data provided under this subsection. Such 

11 safeguards shall only permit the congressional support 

12 agency to disclose the data to another agency or enti13 ty if the agency or entity is— 

14 ‘‘(A) under a subcontract with the congres15 sional support agency to support any analysis 

16 conducted by the congressional support agency 

17 with respect to such data; and 

18 ‘‘(B) is subject to the same data disclosure 

19 provisions and safeguards as the congressional 

20 support agency is subject to under this para21 graph and paragraph (2). 

22 ‘‘(4) DISCLOSURE EXEMPTION.—Data provided 

23 under this subsection shall be exempt from disclosure 

24 under section 552 of title 5, United States Code. 


jlentini on PROD1PC65 with BILLS
8 

•S 3 RS

1 ‘‘(5) CONGRESSIONAL SUPPORT AGENCY DE2 FINED.—In this subsection, the term ‘congressional 

3 support agency’ means— 

4 ‘‘(A) the Medicare Payment Advisory Com5 mission; 

6 ‘‘(B) the Congressional Research Service; 

7 ‘‘(C) the Congressional Budget Office; and 

8 ‘‘(D) the Government Accountability Office. 

9 ‘‘(6) RESTRICTION ON DISCLOSURE OF PRICE

10 CONCESSIONS.—The Secretary may only release data 

11 on the negotiated price concessions described in para12 graph (1)(B) to the congressional support agency de13 scribed in paragraph (5)(C). 

14 ‘‘(7) RULE OF CONSTRUCTION.—Nothing in this 

15 subsection shall be construed to limit the ability of a 

16 congressional support agency to obtain information 

17 not described in paragraph (1).’’. 

18 (b) STUDY ON MARKET COMPETITION AND REPORTS

19 ON LIMITATIONS OF DATA ELEMENTS FOR STUDYING THE

20 PRESCRIPTION DRUG PROGRAM.— 

21 (1) STUDY AND REPORT ON MARKET COMPETI22 TION BY THE CONGRESSIONAL BUDGET OFFICE.— 

23 (A) IN GENERAL.—The Director of the Con24 gressional Budget Office shall conduct a study on 

25 the effect of market competition on prices for 


jlentini on PROD1PC65 with BILLS
9 

•S 3 RS

1 drugs under part D of title XVIII of the Social 

2 Security Act (42 U.S.C. 1395w–101 et seq.) that 

3 includes a review of— 

4 (i) the number and extent of discounts 

5 and other price concessions received by pre6 scription drug plans and MA–PD plans for 

7 covered part D drugs under such part; 

8 (ii) the relationship between such dis9 counts and price concessions and drug utili10 zation; 

11 (iii) the relationship between such dis12 counts and price concessions and the manu13 facturer’s best price (as defined in section 

14 1927(c)(2)(B) of the Social Security Act (42 

15 U.S.C. 1396r–8(c)(2)(B)) for covered out16 patient drugs; and 

17 (iv) the extent to which the efforts of 

18 the Secretary of Health and Human Serv19 ices (as reported by the Secretary under sec20 tion 1860D–11(k) of the Social Security 

21 Act, as added by section 2(b)) to promote 

22 and ensure access to fair prices for prescrip23 tion drugs under such part have an effect 

24 upon payers in non-Medicare markets. 


jlentini on PROD1PC65 with BILLS
10 

•S 3 RS

1 (B) REPORT.—Not later than 1 year after 

2 the date of enactment of this Act, the Director of 

3 the Congressional Budget Office shall submit a 

4 report containing the results of the study con5 ducted under subparagraph (A). 

6 (2) REPORTS ON LIMITATIONS OF DATA ELE7 MENTS FOR STUDYING THE PRESCRIPTION DRUG PRO8 GRAM.—Not later than 180 days after the date of en9 actment of this Act, the Medicare Payment Advisory 

10 Commission and the Government Accountability Of11 fice shall each submit a report to Congress com12 menting on the limitations on the usefulness of the 

13 data described in subparagraphs (A) through (E) of 

14 section 1860D–42(c)(1), as added by subsection (a), to 

15 inform Congress on negotiated prices for covered part 

16 D drugs (as defined in section 1860D–2(e) of such Act 

17 (42 U.S.C. 1395w–102(e)) under the Medicare pre18 scription drug program. 

19 (c) DISCLOSURE OF DRUG CLAIMS DATA TO THE

20 STATE AGENCY RESPONSIBLE FOR ADMINISTERING THE

21 STATE PLAN UNDER THE MEDICAID PROGRAM.—Section 

22 1860D–42 of the Social Security Act (42 U.S.C. 1395w– 

23 152), as amended by subsection (a), is amended by adding 

24 at the end the following new subsection: 


jlentini on PROD1PC65 with BILLS
11 

•S 3 RS

1 ‘‘(d) DISCLOSURE OF DRUG CLAIMS DATA TO THE

2 STATE AGENCY RESPONSIBLE FOR ADMINISTERING THE

3 STATE PLAN UNDER THE MEDICAID PROGRAM.—Notwith4 standing any provision under this part that limits the use 

5 of prescription drug data collected under this part, upon 

6 the request of a State agency with responsibility for admin7 istering the State plan under title XIX, the Secretary shall 

8 provide such State agency with the data described in para9 graph (1)(C) of subsection (c) with respect to full-benefit 

10 dual eligible individuals (as defined in section 1935(c)(6)) 

11 who are enrolled in the State plan. The provisions of para12 graphs (2) and (3) of subsection (c) shall apply to a State 

13 agency with respect to data provided under this subsection 

14 in the same manner as such provisions apply to a congres15 sional support agency with respect to data provided under 

16 subsection (c).’’. 

17 (d) PUBLIC DISCLOSURE OF DATA BY THE SECRETARY

18 OF HEALTH AND HUMAN SERVICES.—Section 1860D–42 of 

19 the Social Security Act (42 U.S.C. 1395w–152), as amend20 ed by subsections (a) and (c), is amended by adding at the 

21 end the following new subsection: 

22 ‘‘(e) DISCLOSURE OF DRUG PRICES CHARGED TO EN23 ROLLEES.— 

24 ‘‘(1) IN GENERAL.—The Secretary shall make 

25 available to the public, upon request and in an elecVerDate Aug 31 2005 21:10 Apr 13, 2007 Jkt 059200 PO 00000 Frm 00011 Fmt 6652 Sfmt 6203 E:\BILLS\S3.RS S3

jlentini on PROD1PC65 with BILLS
12 

•S 3 RS

1 tronic form determined appropriate by the Secretary, 

2 data on the prices charged for each covered part D 

3 drug under each prescription drug plan and MA–PD 

4 plan to individuals enrolled in the plan. Such data 

5 shall reflect actual prices posted on the Internet 

6 website of the Centers for Medicare & Medicaid Serv7 ices and shall be made available in a manner that 

8 permits linkage of the data to data contained in other 

9 public prescription drug plan and MA–PD plan data 

10 files. 

11 ‘‘(2) NOMINAL FEE FOR DATA PROVIDED.—The 

12 Secretary may charge a nominal fee for data pro13 vided under paragraph (1) based on the cost of pre14 paring and providing such data.’’. 

15 (e) DISSEMINATION OF RETAIL DRUG PRICES.—Sec16 tion 1860D–4(k) of the Social Security Act (42 U.S.C. 

17 1395w–104(k)) is amended— 

18 (1) in the heading, by striking ‘‘PHARMA19 CEUTICAL PRICES FOR EQUIVALENT DRUGS’’ and in20 serting ‘‘PRESCRIPTION DRUG INFORMATION AT

21 POINT OF SALE’’; 

22 (2) by striking ‘‘IN GENERAL.—A PDP spon23 sor’’ and inserting ‘‘PHARMACEUTICAL PRICES

24 FOR EQUIVALENT DRUGS.— 

25 ‘‘(A) IN GENERAL.—A PDP sponsor’’; 


jlentini on PROD1PC65 with BILLS
13 

•S 3 RS

1 (3) by redesignating paragraph (2) as subpara2 graph (B) and indenting appropriately; 

3 (4) by redesignating subparagraphs (A) and (B) 

4 as clauses (i) and (ii), respectively, and indenting ap5 propriately; 

6 (5) in clause (i), as redesignated under para7 graph (4)— 

8 (A) by striking ‘‘subparagraph (B)’’ and in9 serting ‘‘clause (ii)’’; and 

10 (B) by striking ‘‘paragraph (1)’’ and insert11 ing ‘‘subparagraph (A)’’; and 

12 (6) by adding at the end the following new para13 graph: 

14 ‘‘(2) DRUG PRICES CHARGED TO ENROLLEES.— 

15 ‘‘(A) IN GENERAL.—A PDP sponsor offering 

16 a prescription drug plan shall provide that each 

17 pharmacy that dispenses a covered part D drug 

18 shall inform an enrollee of the price charged for 

19 such drug under the prescription drug plan. 

20 ‘‘(B) TIMING OF NOTICE.—The information 

21 under subparagraph (A) shall be provided at the 

22 time of purchase of the drug involved, including 

23 for purchases of covered part D drugs by mail 

24 order.’’. 


jlentini on PROD1PC65 with BILLS
14 

•S 3 RS

1 SEC. 4. PRIORITIZING STUDIES OF COMPARATIVE CLINICAL 

2 EFFECTIVENESS OF COVERED PART D DRUGS. 

3 (a) PRIORITIES.— 

4 (1) IN GENERAL.—The Secretary of Health and 

5 Human Services (in this section referred to as the 

6 ‘‘Secretary’’) shall develop a comprehensive 

7 prioritized list of comparative clinical effectiveness 

8 studies that are most critical to building the evidence 

9 needed to advance value-based purchasing of covered 

10 part D drugs (as defined in section 1860D–2(e) of the 

11 Social Security Act (42 U.S.C. 1395w–102(e)) under 

12 the Medicare prescription drug program under part 

13 D of title XVIII of such Act. 

14 (2) REQUIREMENTS.— 

15 (A) DEVELOPMENT OF LIST.—In developing 

16 the list under paragraph (1), the Secretary shall 

17 take into account— 

18 (i) the work the Agency for Healthcare 

19 Research and Quality has already done to 

20 identify needed comparative clinical effec21 tiveness and safety research on prescription 

22 drugs, including the work identifying issues 

23 for which existing scientific evidence is in24 sufficient under subsection (a)(3)(A)(ii) of 

25 section 1013 of the Medicare Prescription 


jlentini on PROD1PC65 with BILLS
15 

•S 3 RS

1 Drug, Improvement, and Modernization Act 

2 of 2003 (42 U.S.C. 299b–7); 

3 (ii) the initial list of medical condi4 tions considered a priority for research that 

5 was developed in response to the require6 ments of subsection (a)(2)(B) of such section 

7 1013; 

8 (iii) areas where patients and doctors 

9 are most lacking the information needed to 

10 make the best decisions regarding covered 

11 part D drugs, such as the areas where there 

12 is a large gap in knowledge of drug thera13 pies and areas that involve the most widely 

14 prescribed covered part D drugs; and 

15 (iv) any advice provided by the advi16 sory committee established under paragraph 

17 (3). 

18 (B) CONTENTS OF PRIORITIZED LIST.— 

19 (i) SPECIFICATION OF ITEMS, SERV20 ICES, AND METHODOLOGY.—The prioritized 

21 list shall specify the items and services to be 

22 evaluated, as well as the general method23 ology that should be used to conduct each 

24 study identified as a priority on the list, 

25 taking into consideration the full range of 


jlentini on PROD1PC65 with BILLS
16 

•S 3 RS

1 methodologies available, from systematic re2 views to clinical trials. 

3 (ii) STUDIES INCLUDED.—The studies 

4 included on the prioritized list may include 

5 studies that compare a covered part D drug 

6 to any other drug (or biological product), 

7 item, or service that is covered under the 

8 Medicare program. 

9 (C) REPORT TO CONGRESS.— 

10 (i) IN GENERAL.—Not later than 1 

11 year after the date of enactment of this Act 

12 and subject to the requirements under clause 

13 (ii), the Secretary shall submit to Congress 

14 a report that contains the following: 

15 (I) The prioritized list developed 

16 under paragraph (1) and plans for the 

17 conduct of studies identified as a pri18 ority on such list. 

19 (II) A summary of the informa20 tion described in clauses (i) through 

21 (iv) of subparagraph (A). 

22 (III) An explanation of how the 

23 Secretary took into account the infor24 mation described in such clauses (i) 

25 through (iv) in developing the 


jlentini on PROD1PC65 with BILLS
17 

•S 3 RS

1 prioritized list and in preparing the 

2 report. 

3 (IV) The rationale for why the 

4 Secretary included the studies identi5 fied as a priority on such list. 

6 (ii) SUBMISSION OF DRAFT REPORT.— 

7 Before submitting the report under clause 

8 (i), the Secretary shall— 

9 (I) submit to Congress a draft 

10 version of the report; 

11 (II) make such draft version 

12 available to the public; and 

13 (III) provide a 60-day period for 

14 public comment on such draft version. 

15 (D) AVAILABILITY OF REPORT.—The Sec16 retary shall make the report submitted under 

17 subparagraph (C)(i) available to the public. 

18 (3) ESTABLISHMENT OF ADVISORY COM19 MITTEE.— 

20 (A) ESTABLISHMENT.—The Secretary shall 

21 establish an advisory committee for the purpose 

22 of providing advice to the Secretary on setting 

23 priorities for comparative clinical effectiveness 

24 studies across all agencies of the Department of 

25 Health and Human Services. The Secretary shall 


jlentini on PROD1PC65 with BILLS
18 

•S 3 RS

1 make available to the public any advice provided 

2 to the Secretary by the advisory committee. 

3 (B) MEMBERSHIP.— 

4 (i) IN GENERAL.—The advisory com5 mittee shall include a diverse range of pub6 lic and private clinical experts, stake7 holders, and interests from the following 

8 groups: 

9 (I) The medical and health indus10 tries. 

11 (II) Patients and representatives 

12 of patients. 

13 (III) Researchers. 

14 (IV) Government. 

15 (ii) NO MAJORITY OF MEMBERSHIP

16 FROM ANY ONE GROUP.—The Secretary 

17 shall ensure that the advisory committee 

18 does not have a majority of members from 

19 any one of the groups described in sub20 clauses (I) through (IV) of clause (i). 

21 (C) PUBLIC COMMENT.—The Advisory com22 mittee shall provide a substantial opportunity 

23 for public comment by accepting oral and writ24 ten comments from the public prior to making 


jlentini on PROD1PC65 with BILLS
19 

•S 3 RS

1 any recommendations or providing any advice to 

2 the Secretary. 

3 (b) RULE OF CONSTRUCTION.—Nothing in this section 

4 shall be construed to limit the authority of the Secretary— 

5 (1) to prioritize comparative clinical effective6 ness research needs for procedures, devices, 

7 diagnostics, or other medical interventions; or 

8 (2) to conduct any study on the list developed 

9 under subsection (a)(1) or any other study determined 

10 appropriate by the Secretary. 

11 (c) AUTHORIZATION OF APPROPRIATIONS.—There are 

12 authorized to be appropriated such sums as may be nec13 essary to carry out this section. 

14 SEC. 5. AUTHORIZING CONSIDERATION OF COMPARATIVE 

15 CLINICAL EFFECTIVENESS STUDIES IN DE16 VELOPING AND REVIEWING FORMULARIES 

17 UNDER THE MEDICARE PRESCRIPTION DRUG 

18 PROGRAM. 

19 (a) IN GENERAL.—Section 1860D–4(b)(3)(B) of the 

20 Social Security Act (42 U.S.C. 1395w–104(b)(3)(B)) is 

21 amended— 

22 (1) in clause (i), by striking ‘‘and’’ at the end; 

23 (2) in clause (ii), by striking the period at the 

24 end and inserting ‘‘; and’’; and 


jlentini on PROD1PC65 with BILLS
20 

•S 3 RS

1 (3) by adding at the end the following new 

2 clause: 

3 ‘‘(iii) take into account relevant com4 parative clinical effectiveness studies.’’. 

5 (b) EFFECTIVE DATE.—The amendments made by sub6 section (a) shall apply to plan years beginning on or after 

7 January 1, 2007. 

8 SEC. 6. SENSE OF THE SENATE REGARDING THE RESOURCE 

9 STANDARD USED TO DETERMINE ELIGIBILITY 

10 FOR PREMIUM AND COST-SHARING SUB11 SIDIES UNDER PART D. 

12 (a) FINDINGS.—The Senate makes the following find13 ings: 

14 (1) Currently, beneficiaries enrolled in the Medi15 care part D prescription drug program must satisfy 

16 a resource standard in order to be eligible for the low17 income subsidy. 

18 (2) The resource standard used to determine eli19 gibility for the low-income subsidy has resulted in 

20 many Medicare beneficiaries who are in financial 

21 need being disqualified from receiving additional as22 sistance. 

23 (3) Under S. 1 from the 108th Congress, as 

24 passed by the Senate, beneficiaries were not subjected 


jlentini on PROD1PC65 with BILLS
21 

•S 3 RS

1 to a resource standard to qualify for additional as2 sistance. 

3 (b) SENSE OF THE SENATE.—It is the Sense of the 

4 Senate that Congress should revisit the resource standard 

5 used to determine the eligibility of individuals for premium 

6 and cost-sharing subsidies under section 1860D–14 of the 

7 Social Security Act (42 U.S.C. 1395w–114). 

8 SEC. 7. SENSE OF THE SENATE REGARDING PHARMACY 

9 ISSUES UNDER PART D. 

10 (a) FINDINGS.— 

11 (1) Pharmacists play a critical role in delivering 

12 prescription drugs to Medicare beneficiaries enrolled 

13 in prescription drug plans and MA–PD plans under 

14 the Medicare part D prescription drug program. 

15 (2) Pharmacists have encountered difficulties in 

16 providing services under their contracts with PDP 

17 sponsors offering prescription drug plans and MA or18 ganizations offering MA–PD plans under part D. 

19 (b) SENSE OF THE SENATE.—It is the sense of the Sen20 ate that Congress should address issues related to phar21 macies under the Medicare part D prescription drug pro22 gram. 


jlentini on PROD1PC65 with BILLS
Calendar No. 118 

110TH CONGRESS 

1ST SESSION S. 3 

A BILL 

To amend part D of title XVIII of the Social Secuprices for Medicare beneficiaries. rity Act to provide for fair prescription drug 

APRIL 13, 2007 

Reported with an amendment 


jlentini on PROD1PC65 with BILLS